Finance entity

Lantheus Holdings

Company LNTH

All 2 tracked stories fall under one category: earnings. Lantheus Holdings is most often covered alongside Heron Therapeutics, which appears in 2 of these 2 stories. Source depth averages 3 original sources per story, versus 2.7 across the same-window beat baseline.

Last mentioned: Feb 26, 2026

Entity pulse

Recent coverage · Lantheus Holdings

2 stories
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Lantheus Holdings

All 2 tracked stories fall under one category: earnings. Lantheus Holdings is most often covered alongside Heron Therapeutics, which appears in 2 of these 2 stories. Source depth averages 3 original sources per story, versus 2.7 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 5.9. We currently track 2 Finance stories that mention Lantheus Holdings, published between February 25, 2026 and February 26, 2026.

Stories tracked
2
Sources per story
3

Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 216 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Lantheus Holdings. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Lantheus Holdings 2

Earnings Neutral

Mid-Cap Biotech Resilience: Lantheus and Heron Navigate Mixed Q4 Results

Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter results for 2025, characterized by revenue growth offset by margin pressures. Crucially, both firms took the rare step of introducing fiscal year 2026 guidance, signaling a strategic shift toward long-term stability in the radiopharmaceutical and acute care markets.

2 sources
Earnings Neutral

Biotech Earnings Preview: Delcath, Butterfly, Heron, and Lantheus Set Q4 Outlook

As the Q4 2025 earnings season intensifies, four key players in the specialized medical technology and biotechnology sectors—Delcath Systems, Butterfly Network, Heron Therapeutics, and Lantheus Holdings—are preparing to report results. Investors are focusing on commercial execution, product adoption rates, and the sustainability of high-growth specialized therapies.

4 sources

Lantheus Holdings is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.